Behind Sanofi’s Diabetes and Cardiovascular Portfolio in 3Q17


Dec. 28 2017, Updated 7:30 a.m. ET

Diabetes and cardiovascular franchise

Sanofi’s (SNY) diabetes and cardiovascular portfolio includes Lantus, Toujeo, Multaq, and Praluent. These drugs reported revenues of 1.67 billion euros for 3Q17, representing a 9.1% YoY (year-over-year) fall in operating revenues, including revenues from emerging markets.

Excluding revenues from emerging markets, the franchise reported revenues of 1.30 billion euros for 3Q17—a 14.8% YoY decline.

Article continues below advertisement

Cardiovascular products

SNY’s cardiovascular products include Multaq and Praluent. The combined revenues for these drugs was 123 million euros in 3Q17, or 4% higher YoY, including revenues from emerging markets.

If we exclude revenues from emerging markets, Multaq sales fell 4.6% to 80 million euros in 3Q17, while Praluent sales rose 26.5% to 41 million euros.

Diabetes products

SNY’s diabetes products include Lantus and Toujeo. Diabetes products reported revenues of 1.55 billion euros in 3Q17, or 10% lower YoY, including revenues from emerging markets. If we exclude emerging markets sales, diabetes products reported revenues of 1.18 billion euros for 3Q17—a 16.3% YoY fall.

Lantus reported revenues of 867 million euros for 3Q17, which was 22% lower YoY, excluding emerging market sales. This fall was driven by lower sales from the US and in European markets.

Toujeo reported revenues of 179 million euros in 3Q17—14% higher YoY—excluding emerging market sales. This growth was driven by strong sales from all major markets outside the US.

Notably, the VanEck Vectors Pharmaceuticals ETF (PPH) has 4.8% of its total investments in Sanofi ADR (SNY), 4.3% in Eli Lilly (LLY), 4.7% in Mylan NV (MYL), and 4.9% in Merck (MRK).


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.